Provided herein are methods for making liposomal API formulations via continuous in-line diafiltration processes. Also provided herein are liposomal API formulations manufactured by the disclosed methods.

Provided herein are methods for making liposomal API formulations via continuous in-line diafiltration processes. Also provided herein are liposomal API formulations manufactured by the disclosed methods.

Disclosed compositions comprise a therapeutic agent and a carrier selected, or processed to have, an acceptable composite flow index, a granular particle size of 18 mesh to 80 mesh, or both, such as processed granular wheat middlings. The composition may also comprise an oil and/or micro tracers. Suitable granular wheat middlings may have a size range of from 18 mesh to 80 mesh, such as 20 mesh to 80 mesh. The composition has improved flowability characteristics, compared to a composition where the carrier, such as processed wheat middlings, are powdered and/or flakey. Certain embodiments concern a composition comprising, consisting essentially of, or consisting of, nicarbazin, granular wheat middlings, soybean oil and micro tracers. The composition may be administered to an animal, for example, to treat or prevent coccidiosis. Also disclosed herein are methods for making and using the composition.

Disclosed compositions comprise a therapeutic agent and a carrier selected, or processed to have, an acceptable composite flow index, a granular particle size of 18 mesh to 80 mesh, or both, such as processed granular wheat middlings. The composition may also comprise an oil and/or micro tracers. Suitable granular wheat middlings may have a size range of from 18 mesh to 80 mesh, such as 20 mesh to 80 mesh. The composition has improved flowability characteristics, compared to a composition where the carrier, such as processed wheat middlings, are powdered and/or flakey. Certain embodiments concern a composition comprising, consisting essentially of, or consisting of, nicarbazin, granular wheat middlings, soybean oil and micro tracers. The composition may be administered to an animal, for example, to treat or prevent coccidiosis. Also disclosed herein are methods for making and using the composition.

Disclosed compositions comprise a therapeutic agent and a carrier selected, or processed to have, an acceptable composite flow index, a granular particle size of 18 mesh to 80 mesh, or both, such as processed granular wheat middlings. The composition may also comprise an oil and/or micro tracers. Suitable granular wheat middlings may have a size range of from 18 mesh to 80 mesh, such as 20 mesh to 80 mesh. The composition has improved flowability characteristics, compared to a composition where the carrier, such as processed wheat middlings, are powdered and/or flakey. Certain embodiments concern a composition comprising, consisting essentially of, or consisting of, nicarbazin, granular wheat middlings, soybean oil and micro tracers. The composition may be administered to an animal, for example, to treat or prevent coccidiosis. Also disclosed herein are methods for making and using the composition.

In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.

In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.

The present disclosure relates to a pharmaceutical composition for preventing or treating statin-induced adverse effects or a pharmaceutical composition for co-administration with statin, the pharmaceutical composition containing, as an active ingredient, at least one selected from the group consisting of an isoprenoid-based compound, zaragozic acid, terbinafine, and ketoconazole. The pharmaceutical composition according to the present disclosure may prevent and/or treat adverse statin effects that can be induced by statin, that is, can be induced at any time by oxisterols present at abnormal levels in the body. The pharmaceutical composition can not only treat but also prevent the adverse effects of various statin therapeutics whose use has recently increased rapidly, and thus it is expected that the pharmaceutical composition can be widely used for various diseases and the utilization thereof can further be increased.

The present disclosure relates to a pharmaceutical composition for preventing or treating statin-induced adverse effects or a pharmaceutical composition for co-administration with statin, the pharmaceutical composition containing, as an active ingredient, at least one selected from the group consisting of an isoprenoid-based compound, zaragozic acid, terbinafine, and ketoconazole. The pharmaceutical composition according to the present disclosure may prevent and/or treat adverse statin effects that can be induced by statin, that is, can be induced at any time by oxisterols present at abnormal levels in the body. The pharmaceutical composition can not only treat but also prevent the adverse effects of various statin therapeutics whose use has recently increased rapidly, and thus it is expected that the pharmaceutical composition can be widely used for various diseases and the utilization thereof can further be increased.

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and a statin and to methods of using the same to treat or prevent cardiovascular-related diseases.